Navigation Links
AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2,Data for Ozarelix, in BPH at Annual AUA Meeting

Ozarelix improved LUTS symptoms and urine flow over 28-week period

QUEBEC CITY, May 23, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner Spectrum Pharmaceuticals presented an abstract outlining detailed Phase 2 results for AEterna Zentaris' fourth-generation luteinizing hormone-releasing hormone (LHRH/GnRH) antagonist, ozarelix, in benign prostatic hyperplasia (BPH). Results indicate that ozarelix was well tolerated and demonstrated statistically significant as well as clinically meaningful efficacy in the treatment of lower urinary tract symptoms (LUTS) secondary to BPH. Results also showed no statistically significant impact on quality of life or erectile function. The abstract was presented yesterday afternoon at the American Urological Association (AUA) Annual Meeting being held this week at the Anaheim Convention Center in Anaheim, California.

"We are encouraged by these data with ozarelix and look forward to seeing further results from the fully-enrolled Phase 2b trial, said David J. Mazzo, Ph.D., President and CEO of AEterna Zentaris. "With cetrorelix in an ongoing Phase 3 program and ozarelix completing a Phase 2b trial this year, we are fortunate to be leading the LHRH antagonist class with two very promising compounds for the treatment of BPH."

Details

The abstract #93629 (Poster #1552) titled, "The efficacy and safety of ozarelix, a novel GnRH antagonist in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)" reviewed results of a randomized, double-blind, placebo-controlled, multi-center, dose-ranging Phase 2 trial in BPH.

Ozarelix was given intramuscularly (IM) to men with moderate to severe LUTS due to BPH, to assess the compound's efficacy and safety. Eligible patients were treated with placebo for 4 weeks to establish b
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:1/15/2014)... 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting ... China,s orthopedic instrument industry has ... size rising from 3.28 billion yuan in 2006 to ...
(Date:1/15/2014)... As health officials across the Midwest warn against the ... Michigan will offer free diagnostic testing ... pharmacists to administer tests and, in some cases, fill the ... in the study. The Grand Rapids, ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... studies of its NeuroFlo(TM) ... Ischemic Stroke, MINNEAPOLIS, April 1, 2008 CoAxia(TM), ... an additional $11.5M financing,from current investors to support the ... extension of the previously announced,C Round and will allow ...
... 1, 2008 CV Therapeutics, Inc.,(Nasdaq: CVTX ... 57th Annual,Scientific Sessions of the American College of ... reduced the,risk of recurrent ischemia (p=0.002), worsening angina ... patients,(n=3,565) in the MERLIN- TIMI 36 study., ...
Cached Medicine Technology:CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors 2CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina 2CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina 3
(Date:7/9/2014)... -- Vasectomy was associated with a small increased risk ... or lethal prostate cancer according to a new study ... found that the association remained even among men who ... lethal cancer cannot be explained by diagnostic bias. It ... to look at the link between vasectomy and prostate ...
(Date:7/9/2014)... heretofore hidden ways that cells are regulated, scientists at ... cancer cells more likely to metastasize. , What,s more, ... by blocking two other proteins that are normally linked ... processes could have unexpected ties. , The study, ... Nature , points to the possibility of new cancer ...
(Date:7/9/2014)... have found that fecal transplantation is effective and safe ... This is the result of a study led by ... Women,s Gastrointestinal Medicine at The Women,s Medicine Collaborative. The ... advance of print in the American Journal of ... C. diff , has increased to epidemic proportions over ...
(Date:7/9/2014)... in French . ... old teens, including brain structure and function, personality, life experiences ... go on to develop binge drinking within the next two ... variables such as life events and a family history of ... Whether or not the child had had a single drink ...
(Date:7/9/2014)... World Cup highlights, Brian Williams refreshing old school rap ... on railings. A University of Colorado Cancer Center study ... that YouTube also allows researchers, journals, and health advocates ... skin cancer and prevention. , "No matter what field ... we communicate around the world," says Chante Karimkhani, MD ...
Breaking Medicine News(10 mins):Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:What drives a child to abuse alcohol? 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2
... Feb. 19 Given the growing strain placed ... demand for data processing and storage, corporations have ... energy efficiencies immediately. However, according to a Siemens ... to best accomplish new efficiency expectations. The new ...
... of HIEs through American Recovery and Reinvestment Act ... for the integration of health care and technology ... of 2009, Shared Health, one of the largest ... the U.S., has already shown success in implementing ...
... in Washington , D.C. ... 19 At the 6th Annual World Health Care ... driving the $2.4 trillion health care industry. From corporate ... who are responsible for purchasing health care to the ...
... A pair of blood pressure medicines helps maintain proper ... News) -- A combination of two blood pressure-lowering drugs ... percent in people with type 2 diabetes, according to ... more than 11,000 patients. , The patients were randomly ...
... 19 Healthcare has always been a vital issue for ... new industry -- financial wellness. The two are far more ... Press and AOL Health found that debt stress is a ... more likely to have health problems, 20% more likely to ...
... BOSTON, Feb. 19 Solos Endoscopy, Inc. (Pink ... Company,s breast endoscopy product line, the MammoView(TM), ... Surgical Products Magazine in the December 2008 issue. ... allow Physicians direct visualization, while examining lesions in ...
Cached Medicine News:Health News:Siemens Survey Reveals Low Awareness of Escalating Need for Superior Data Center Efficiency 2Health News:Siemens Survey Reveals Low Awareness of Escalating Need for Superior Data Center Efficiency 3Health News:Shared Health(R) Proves Health Information Exchange (HIE)Success in Tennessee 2Health News:Shared Health(R) Proves Health Information Exchange (HIE)Success in Tennessee 3Health News:6th Annual World Health Care Congress to Convene Preeminent Leaders for Three Days on Rebuilding Health Care 2Health News:6th Annual World Health Care Congress to Convene Preeminent Leaders for Three Days on Rebuilding Health Care 3Health News:Two-Drug Combo May Lower Diabetics' Kidney Risk 2Health News:Recession Spawns Vital New Industry - Financial Wellness 2Health News:Recession Spawns Vital New Industry - Financial Wellness 3Health News:Solos Endoscopy, Inc.'s MammoView(TM) Featured in December Issue of Surgical Products Magazine 2
This Implant enhances and restores the nasal contour, The large selection of sizes with a variety of flares and lengths allows for more individualized results...
... designed to enhance the chin contour, this chin ... a high-profile central chin projection. Symmetrical Chin ... this implant provides a high central projection, as ... Cleft Chin Implants - Designed with a unique ...
The MiniMed Paradigm REAL-Time System is the world's first system to integrate an insulin pump with REAL-Time continuous glucose monitoring, taking diabetes management to a level you just can't achie...
... IEC CL31 Multispeed Series offers unsurpassed ... quiet, compact, 1.2 liter benchtop centrifuge. ... and accessories and high-speed centrifugation capabilities, ... everything you need to meet a ...
Medicine Products: